EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ACRS: Aclaris Therapts

12 Nov 25 13:04
LAST:

2.410

CHANGE:
 0.11		OPEN:
2.310		HIGH:
2.440		ASK:
22.150		VOLUME:
572.4K
CHG(%):
4.78		PREV:
2.300		LOW:
2.250		BID:
12.250		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Nov 252.3102.4402.2502.410572.4K
11 Nov 252.1002.3402.1002.300970.0K
10 Nov 252.3402.4692.1202.1301.11M
07 Nov 252.2602.3552.1502.3201.14M
06 Nov 252.2902.6392.1952.2702.84M
05 Nov 252.3602.3602.1302.2603.55M
04 Nov 252.5002.6002.3102.3601.11M
03 Nov 252.6502.7002.4002.5601.24M
31 Oct 252.4502.6202.4402.5201.23M
30 Oct 252.3102.4902.2702.4901.32M

COMPANY PROFILE

Name:Aclaris Therapts
About:Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Sector:Healthcare
Industry:Biotechnology
Address:701 Lee Road, Wayne, PA, United States, 19087
Website:https://www.aclaristx.com
CUSIP:00461U105
CIK:0001557746
ISIN:US00461U1051
FIGI:BBG003LF0QR9
LEI:5493000B2LQ9QTW1DF52

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.50 
Forward P/E:-4.34 
PEG Ratio:0.11 
Price to Sales:16.26 
Price to Book:2.07 
Profit Margin:0.17 
Operating Margin:-9.51 
Return on Assets:-0.21 
Return on Equity:-1.01 
EPS Ratio:-1.57 
Revenue:16.79M 
EBITDA:37.69M 
Shares:108.33M 
Market Cap:261.08M 

TECHNICAL INDICATORS

MA5:2.295.4%
MA10:2.362.0%
MA20:2.295.5%
MA50:2.0716.6%
MA100:1.8629.9%
MA200:1.7339.7%
STO9:49.12
STO14:49.12
RSI14:55.17
WPR14:-34.88
MTM14:0.26
ROC14:0.12 
ATR:0.25 
Week High:2.649.5%
Week Low:2.1014.8%
Month High:2.7012.0%
Month Low:1.7439.7%
Year High:5.17114.5%
Year Low:1.05129.5%
Volatility:37.70